University of Vermont

The University of Vermont Cancer Center


Melanoma Clinical Trials

The University of Vermont Cancer Center has many trials specifically focused on skin cancer research.

Status: Active - Recruiting

Study Title: A 2-part Phase III Randomized, Open Label, Multicenter Study of LGX818 Plus MEK162 Versus Vemurafib and LGX818 Monotherapy in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

Purpose: This is a 2-part, randomized, open label, multi-center, parallel group, phase III study comparing the efficacy and safety of LGX818 plus MEK162 to vemurafenib and LGX818 monotherapy in patients with locally advanced unresectable or metastatic melanoma with BRAF V600 mutation. Identifier: NCT01909453
Contact: Jane Walsh (802) 656-9926
Institution Number: 14-174
Protocol Research Type: Industry Sponsored
Status: Active - Closed to Accrual

Study Title: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma

Purpose: The purpose of this study is to compare the effects, good and/or bad, of ipilimumab with interferon alfa-2b on you and your melanoma to find out which is better.  In this study, you will get either ipilimumab or the interferon alfa-2b. You will not get both. We plan to determine whether ipilimumab stops or delays your cancer from returning in comparison to interferon alfa-2b. Identifier: N/A
Primary/Site/Co Investigator: Steven Emmons, MD
Contact: Jane Walsh (802) 656-9926
Information: N/A
Institution Number: M12-125 ECOG-ACRIN 1609
Protocol Research Type: Cooperative Group - ECOG-ACRIN

Last modified February 18 2016 02:04 PM